

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 036 797 A1**

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:
20.09.2000 Bulletin 2000/38

(51) Int. Cl.⁷: **C07H 15/252**

(21) Application number: 98956000.8

(86) International application number:
PCT/JP98/05391

(22) Date of filing: 01.12.1998

(87) International publication number:
WO 99/29708 (17.06.1999 Gazette 1999/24)

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

(30) Priority: 05.12.1997 JP 35015797

(71) Applicant: **MERCIAN CORPORATION**
Chuo-ku, Tokyo 104-8305 (JP)

(72) Inventors:
• **JOHDO, Osamu**
Fujisawa-shi, Kanagawa 252-0804 (JP)

• **NAKAMURA, Kiyotomo**
Yatsushiro-shi, Kumamoto 866-0884 (JP)
• **YOSHIOKA, Takeo**
Ayase-shi, Kanagawa 252-1124 (JP)

(74) Representative:
Albrecht, Thomas, Dr.
Kraus, Weisert & Partner
Patent- und Rechtsanwälte
Thomas-Wimmer-Ring 15
80539 München (DE)

(54) **CRYSTALLINE ANTHRACYCLINE ANTIBIOTIC AND PROCESS FOR PRODUCING THE SAME**

(57) Disclosed are a crystalline form of anthracycline antibiotic having specific characteristic 2 θ values as measured by the X-ray diffraction method, and a process for producing the crystalline form. This process comprises the step of crystallization involving the combined use of a specific poor solvent for the antibiotic and a good solvent therefor. This crystalline form has excellent chemical and physical properties.


EP 1 036 797 A1

Description**Technical Field**

- 5 [0001] This invention relates to novel crystalline forms of an anthracycline antibiotic, particularly daunomycin (also known as daunorubicin), and a process for producing the same.

Background Art

- 10 [0002] Daunomycin (also known as daunorubicin; hereinafter abbreviated as DM), which is an anthracycline antibiotic represented by the following formula (I)



- 30 is known to be obtained from a culture medium of an actinomycete, and has a wide anticancer spectrum against experimental animal tumors. As a matter of fact, DM is being widely used as a chemotherapeutic agent for cancer in clinical applications.

- 35 [0003] However, the currently available bulk form of DM (DM hydrochloride) is an amorphous powder or a solid which is tentatively classified as crystalline but has high hygroscopicity and poor stability. From the viewpoint of the preparation of DM into medicines, the physical and chemical properties of not only its final bulk powder but also its intermediate products have a great significance. For example, poor chemical stability requires great caution in storage, and high hygroscopicity makes its handling difficult. Moreover, with consideration for its use as a drug, any residual solvent may constitute a fatal shortcoming.

- 40 [0004] Accordingly, an object of the present invention is to provide a solid product of DM hydrochloride having excellent chemical stability and, preferably, further having low hygroscopicity and an allowable residual solvent content.

Disclosure of the Invention

- 45 [0005] The present inventors made repeated investigations with a view to solving the above-described problems and have now found that the crystallization of DM hydrochloride by using a certain solvent system yields a specific crystalline form of DM hydrochloride having excellent chemical stability and, in some instances, this crystalline form also has low hygroscopicity and can solve the problem with residual solvent.

- [0006] Thus, according to the present invention, there is provided a crystalline form of DM hydrochloride having at least characteristic 2θ values (in degrees) of 6.18, 7.88, 9.82, 11.60, 13.30, 15.80, 20.88 and 23.12 as measured by the X-ray powder diffraction method.

- 50 [0007] According to the present invention, there is also provided a process for producing the aforesaid crystalline form of DM hydrochloride from a solution containing DM hydrochloride, the process comprising the steps of preparing the aforesaid solution by using a solvent system composed of a poor solvent for the antibiotic and a good solvent which is miscible with the poor solvent and capable of dissolving the antibiotic; and subjecting the solution so prepared to a crystallization treatment.

55

Brief Description of the Drawing**[0008]**

5 FIG. 1 is a chart showing the results of X-ray powder diffraction analysis of DM hydrochloride powders and various crystalline forms of DM hydrochloride. In this chart, b) shows the result of X-ray powder diffraction analysis of a crystalline form of DM hydrochloride in accordance with the present invention; a), d), e) and f) show the results of X-ray powder diffraction analysis of amorphous DM hydrochloride powders (comparative powders); and c), g) and h) show the results of X-ray powder diffraction analysis of solid forms of DM hydrochloride which are regarded as crystalline but do not show the properties of the crystalline form in accordance with the present invention (comparative crystalline forms).

Specific Description of the Invention

15 **[0009]** Specifically, the crystalline form of DM hydrochloride in accordance with the present invention are characterized by having at least characteristic 2θ values (in degrees) of 6.18, 7.88, 9.82, 11.60, 13.30, 15.80, 20.88 and 23.12 as measured by the X-ray powder diffraction method (the Debye-Scherrer method) [see b) in FIG. 1]. The term "crystalline form" as used herein means a single crystal or a mass of such crystals, and the aforesaid results of X-ray powder diffraction analysis are those obtained from such masses.

20 **[0010]** The crystalline form in accordance with the present invention are clearly distinguished from amorphous powders [corresponding to those shown as a), d), e) and f) in FIG. 1] and solid forms tentatively regarded as crystalline [corresponding to those shown as c), g) and h) in FIG. 1]. Moreover, as will be described later, the crystalline form b) have very excellent properties from the viewpoints of hygroscopicity, residual solvent and chemical stability.

25 **[0011]** Generally and not by way of limitation, the process for producing the aforesaid crystalline form in accordance with the present invention comprises the steps of preparing a solution by dissolving a DM hydrochloride powder having a relative purity of greater than 90% in a solvent capable of dissolving the DM; and crystallizing the DM by adding to the solution a solvent which is miscible with the aforesaid solvent but is a poor solvent for DM.

30 **[0012]** It is important to use a solvent containing at least 1-butanol as the aforesaid poor solvent. Typical examples of such solvents include 1-butanol alone and solvent mixtures composed of 1-butanol and other organic solvents (e.g., acetone, hexane and diisopropyl ether). On the other hand, as the solvent capable of dissolving DM, there may be used any solvent that can dissolve DM, is miscible the aforesaid poor solvent, and hence suits the purpose of the present invention. Typical examples of such solvents include, but are not limited to, water, methanol, ethanol, and mixtures of two or more of them.

35 **[0013]** In accordance with a preferred embodiment, the production process of the present invention comprises the steps of preparing a solution by dissolving a DM hydrochloride powder having a relative purity of greater than 90% in methanol (for example, by using the DM hydrochloride powder and methanol in a weight ratio of 1 : 5 to 1 : 20); and crystallizing the DM by adding 1-butanol or a mixture of 1-butanol and acetone, hexane or diisopropyl ether (for example, containing up to 60% of acetone, hexane or diisopropyl ether) to the aforesaid solution in an amount of about 1 to 20 parts by volume as based on the methanol.

40 **[0014]** When the expression "1-butanol/acetone", for example, is used in connection with the present invention, it means the combined use of 1-butanol and acetone. Thus, according to the present invention, the solvent used to dissolve a DM hydrochloride powder may comprise not only methanol alone, but also a mixture of methanol and 1-butanol or a mixture of methanol, 1-butanol and acetone, hexane or diisopropyl ether, provided that the mixture can dissolve the DM hydrochloride powder. Then, as a solvent for crystallization purposes, 1-butanol or a mixture of 1-butanol and acetone, hexane or diisopropyl ether is added to the DM hydrochloride solution thus obtained, so that a crystalline DM hydrochloride is formed. This crystallization step may be carried out by, after the addition of the aforesaid solvent for crystallization purposes, allowing the solution to stand at a temperature of about 5 to 35°C and preferably at room temperature (18 to 27°C), optionally with cooling (to about 5°C) and optionally with gentle stirring. The crystalline DM hydrochloride so precipitated may be collected by a per se known technique such as filtration or centrifugation.

50 **[0015]** DM hydrochloride may be obtained as a commercial product, or may be prepared according to the process described in Japanese Patent Laid-Open No. 21394/84 (corresponding to U.S. Patent No. 4,592,999). As the starting material for use in the process of the present invention, the DM hydrochloride which has been obtained by any method may be used, provided that it suits the purpose of the present invention. However, it is generally favorable to use DM hydrochloride having a purity of not less than 90% and preferably not less than 95%.

55 **[0016]** The present invention is more specifically explained with reference to the following examples. However, it is not intended to limit the present invention to any of these examples.

Example 1 (comparative example)

[0017] 2 g of DM hydrochloride was dissolved in 20 mL of methanol. At room temperature, 200 mL of acetone was added to the solution, resulting in the formation of a precipitate. This precipitate was collected by filtration and dried (under reduced pressure at 60°C for 16 hours) to obtain 1.2 g of a reddish-brown powder. The result of measurement of this powder according to the X-ray powder diffraction method is shown as a) in FIG. 1. The measuring conditions included a step angle of 0.02°, a counting time of 1.0 second, a tube voltage of 40.0 kV, and a tube current of 20.0 mA (the same shall apply hereinafter).

Example 2 (the present invention)

[0018] 2 g of DM hydrochloride was dissolved in 20 mL of methanol. At room temperature, 200 mL of 1-butanol was added to the solution, resulting in the formation of a precipitate. This precipitate was collected by filtration and dried (under reduced pressure at 60°C for 16 hours) to obtain 1.4 g of a reddish-brown crystalline powder. The result of measurement of this powder according to the X-ray powder diffraction method is shown as b) in FIG. 1.

Example 3 (comparative example)

[0019] 2 g of DM hydrochloride was dissolved in 20 mL of methanol. At room temperature, 200 mL of ethanol was added to the solution, resulting in the formation of a precipitate. This precipitate was collected by filtration and dried (under reduced pressure at 60°C for 16 hours) to obtain 0.9 g of a reddish-brown crystalline powder. The result of measurement of this powder according to the X-ray powder diffraction method is shown as c) in FIG. 1.

Example 4 (comparative example)

[0020] 2 g of DM hydrochloride was dissolved in 20 mL of methanol. At room temperature, 200 mL of diethyl ether was added to the solution, resulting in the formation of a precipitate. This precipitate was collected by filtration and dried (under reduced pressure at 60°C for 16 hours) to obtain 1.5 g of a reddish-brown powder. The result of measurement of this powder according to the X-ray powder diffraction method is shown as d) in FIG. 1.

Example 5 (comparative example)

[0021] 2 g of DM hydrochloride was dissolved in 20 mL of methanol. At room temperature, 200 mL of 1-propanol was added to the solution, resulting in the formation of a precipitate. This precipitate was collected by filtration and dried (under reduced pressure at 60°C for 16 hours) to obtain 0.9 g of a reddish-brown powder. The result of measurement of this powder according to the X-ray powder diffraction method is shown as e) in FIG. 1.

Example 6 (comparative example)

[0022] 2 g of DM hydrochloride was dissolved in 20 mL of methanol. At room temperature, 200 mL of 2-propanol was added to the solution, resulting in the formation of a precipitate. This precipitate was collected by filtration and dried (under reduced pressure at 60°C for 16 hours) to obtain 1.3 g of a reddish-brown powder. The result of measurement of this powder according to the X-ray powder diffraction method is shown as f) in FIG. 1.

Example 7 (comparative example)

[0023] 2 g of DM hydrochloride was dissolved in 20 mL of methanol. At room temperature, 200 mL of n-hexane was added to the solution, resulting in the formation of a precipitate. This precipitate was collected by filtration and dried (under reduced pressure at 60°C for 16 hours) to obtain 1.3 g of a reddish-brown crystalline powder. The result of measurement of this powder according to the X-ray powder diffraction method is shown as g) in FIG. 1.

Example 8 (comparative example)

[0024] 2 g of DM hydrochloride was dissolved in 20 mL of methanol. At room temperature, 200 mL of isopropyl ether was added to the solution, resulting in the formation of a precipitate. This precipitate was collected by filtration and dried (under reduced pressure at 60°C for 16 hours) to obtain 1.6 g of a reddish-brown crystalline powder. The result of measurement of this powder according to the X-ray powder diffraction method is shown as h) in FIG. 1.

Example 9 (the present invention)

[0025] 0.5 g of DM hydrochloride was dissolved in 5 mL of methanol. At room temperature, 50 mL of a mixture (2 : 3) of 1-butanol and acetone was added to the solution, resulting in the formation of a precipitate. This precipitate was collected by filtration and dried (under reduced pressure at 60°C for 16 hours) to obtain 0.28 g of a reddish-brown crystalline powder. The result of measurement of this powder according to the X-ray powder diffraction method showed the same pattern as that of b) in FIG. 1.

Example 10 (the present invention)

[0026] 0.5 g of DM hydrochloride was dissolved in 5 mL of methanol. At room temperature, 50 mL of a mixture (3 : 2) of 1-butanol and hexane was added to the solution, resulting in the formation of a precipitate. This precipitate was collected by filtration and dried (under reduced pressure at 60°C for 16 hours) to obtain 0.38 g of a reddish-brown crystalline powder. The result of measurement of this powder according to the X-ray powder diffraction method showed the same pattern as that of b) in FIG. 1.

Example 11 (the present invention)

[0027] 0.5 g of DM hydrochloride was dissolved in 5 mL of methanol. At room temperature, 50 mL of a mixture (3 : 2) of 1-butanol and diisopropyl ether was added to the solution, resulting in the formation of a precipitate. This precipitate was collected by filtration and dried (under reduced pressure at 60°C for 16 hours) to obtain 0.38 g of a reddish-brown crystalline powder. The result of measurement of this powder according to the X-ray powder diffraction method showed the same pattern as that of b) in FIG. 1.

Example 12 (tests for hygroscopicity)

[0028] Samples of the powders (or crystalline powders) obtained in Examples 1-8 were stored at 30°C and at relative humidities ranging from 32 to 91%. Their moisture contents were measured until a steady state was reached. The critical relative humidities calculated from the increases or decreases in moisture content are shown in Table 1 below.

Table 1

Powder	Ex.1	Ex.2	Ex.3	Ex.4	Ex.5	Ex.6	Ex.7	Ex.8
Critical relative humidity (%)	34	73	41	28	29	29	41	53

[0029] It can be seen from the above-described results that the crystalline DM hydrochloride obtained in Example 2 (the present invention) has very low hygroscopicity.

Example 13 (tests for chemical stability)

[0030] Each of the same samples as used in Example 12 was placed in a hermetically sealed container and stored at 60°C for 1 month. Then, the sample was analyzed by HPLC to determine the DM content in the sample. The results thus obtained are shown in Table 2 below.

Table 2

Powder	Ex.1	Ex.2	Ex.3	Ex.4	Ex.5	Ex.6	Ex.7	Ex.8
Amount of remaining DM (%)	91.4	100	97.1	90.4	97.5	94.2	97.2	96.5

[0031] It can be seen from the above-described results that the crystalline powder of Example 2 has excellent chemical stability.

(Conditions for analysis by HPLC)

[0032]

- 5 Column: YMC A-312 (ODS) (manufactured by YMC Co., Ltd.).
 Mobile phase: Acetonitrile-water (38 : 62) (adjusted to pH 2.2 with phosphoric acid).
 Flow velocity: About 1.5 ml/min.
 Detection: 254 nm.

10 Example 14 (residual solvent content)

[0033] Each of the same samples as used in Example 12 was analyzed by gas chromatography (GC) to determine its residual solvent content. The results thus obtained are shown in Table 2 below.

15

Table 3

20

Crystalline form								
Powder	Ex.1	Ex.2	Ex.3	Ex.4	Ex.5	Ex.6	Ex.7	Ex.8
Residual solvent content (%)	0.14	0.40	0.03	0.50	0.19	0.18	0.05	0.95

[0034] It can be seen from the above-described results that the residual solvent content of the crystalline powder of Example 2 is within an acceptable limit.

25

(Operating conditions for analysis by GC)

[0035]

- 30 Detector: Flame ionization detector.
 Column: Shimadzu CBP 10-S25-050.
 Column temperature: Operated at 40°C for 5 minutes, and then raised to 80°C in 5 minutes and held at that temperature.
 Vaporization chamber temperature: A constant temperature around 200°.
 35 Carrier gas: Helium.
 Flow rate: A constant flow rate at which the retention time of an internal standard substance (dioxane) is about 6 minutes.

Exploitability in Industry

40

[0036] The present invention provides crystalline forms of DM hydrochloride showing a reduction in hygroscopicity and residual solvent content and an improvement in chemical stability, as well as a process which can produce them easily. Accordingly, the present invention may be utilized, for example, in the field of the manufacture of medicines and bulk materials for medicines.


45

Claims

1. A crystalline form of anthracycline antibiotic represented by the following formula (I) and having at least characteristic 2θ values (in degrees) of 6.18, 7.88, 9.82, 11.60, 13.30, 15.80, 20.88 and 23.12 as measured by the X-ray powder diffraction method.


50

55



(I)

2. A process for producing a crystalline form of anthracycline antibiotic represented by the following formula (I) and having at least characteristic 2 θ values (in degrees) of 6.18, 7.88, 9.82, 11.60, 13.30, 15.80, 20.88 and 23.12 as measured by the X-ray powder diffraction method,




(I)

from a solution containing the antibiotic, the process comprising the steps of preparing said solution by using a solvent system composed of a poor solvent for the antibiotic and a good solvent which is miscible with the poor solvent and capable of dissolving the antibiotic; and subjecting the solution so prepared to a crystallization treatment.

3. A process as claimed in claim 2 wherein the poor solvent contains at least 1-butanol.
4. A process as claimed in claim 2 wherein the poor solvent is selected from the group consisting of 1-butanol, 1-butanol/acetone, 1-butanol/hexane and 1-butanol/diisopropyl ether.
5. A process as claimed in claim 2 wherein the poor solvent is selected from the group consisting of 1-butanol, 1-butanol/acetone, 1-butanol/hexane and 1-butanol/diisopropyl ether, and the good solvent capable of dissolving the antibiotic and used in combination with the poor solvent is selected from the group consisting of water, methanol, ethanol and a mixture of two or more of them.
6. A process as claimed in claim 2 which comprises the steps of dissolving 1 part by weight of the antibiotic of formula (I) in 5 to 20 parts by weight of methanol, adding 1-butanol or a solvent mixture comprising 1-butanol/acetone, 1-butanol/hexane or 1-butanol/diisopropyl ether (in which acetone, hexane or diisopropyl ether may comprise up to 60% by volume of the solvent mixture) to the resulting solution in an amount of 1 to 20 parts by volume based on the volume of methanol, and crystallizing the antibiotic at a temperature in the range of 5 to 35°C.

Fig. 1



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP98/05391

A. CLASSIFICATION OF SUBJECT MATTER Int.Cl. ⁶ C07H15/252		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl. ⁶ C07H15/252		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Caplus (STN), REGISTRY (STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JP, 5-399, B2 (Biogal Gyogyszergyar), 5 January, 1993 (05. 01. 93) & EP, 306541, A & AU, 8775669, A & DK, 8703560, A & FI, 8703062, A & DE, 3775928, G & ES, 2027662, T3	1-6
A	JP, 59-118797, A (Farmitalia Carlo Erba S.p.A.), 9 July, 1984 (09. 07. 84), Refer to Example 2 & BR, 898506, A & DE, 3345445, A & GB, 2133005, A & FR, 2538394, A & NL, 8304327, A & SE, 8307134, A & AU, 8322455, A & DK, 8305940, A & FI, 8304650, A & PT, 77883, A & HU, 35270, T & ES, 8504758, A & CA, 1204738, A & CH, 657623, A & AT, 8304400, A & IT, 1155446, B & US, 4861870, A & KR, 9200102, B1	1-6
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "R" document member of the same patent family		
Date of the actual completion of the international search 8 February, 1999 (08. 02. 99)		Date of mailing of the international search report 16 February, 1999 (16. 02. 99)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

⑨ 日本国特許庁 (JP)

⑩ 特許出願公開

⑫ 公開特許公報 (A)

昭59—118797

⑪ Int. Cl.³
C 07 H 15/24

識別記号

庁内整理番号
7252—4C

⑬ 公開 昭和59年(1984) 7月 9日

発明の数 1
審査請求 未請求

(全 5 頁)

⑭ アントラサイクリノングリコシドの精製法

アシスモンダ 7

⑮ 特 願 昭58—241118

⑯ 出 願 昭58(1983)12月22日

優先権主張 ⑰ 1982年12月23日 ⑱ イタリア
(IT) ⑲ 24939A/82⑳ 発 明 者 エルネスト・オピーチ
イタリア国20127ミラノ・ヴィ
アヴァルトルタ 6㉑ 発 明 者 カルロ・ヴァレーチヨ
イタリア国10145トリノ・ヴィ㉒ 発 明 者 オノリーノ・ジヤコマ・ローサ
イタリア国10090サンラファエ
レチメナ／トリノ・ヴィアパウ
ダーナ27㉓ 出 願 人 ファーミタリア・カルロ・エル
バ・ソシエタ・ペル・アツイオ
ーニイタリア国ミラノ・ヴィアカル
ロイムボナチ24

㉔ 代 理 人 弁理士 山下白

明 細 書

1. 発明の名称 アントラサイクリノングリコシ
ドの精製法

2. 特許請求の範囲

- 1) 粗生成物の水溶液を樹脂上に選択的に吸着させることにより精製を実施することからなるアントラサイクリノングリコシドの精製法。
- 2) 精製すべき粗生成物を含有する溶液を樹脂上に吸着させる前に pH 3～5 とすることからなる前記特許請求の範囲第 1 項記載の方法。
- 3) 吸着に使用される樹脂が重合体状イオン交換吸着樹脂およびカルボキシメチルセルローズからなる群から選択されることからなる前記特許請求の範囲第 1 項記載の方法。
- 4) 精製すべき粗生成物を含有する溶液の樹脂への吸着がただ 1 種の型の樹脂を用いることにより、または不純物の性質に応じて異なる

型の樹脂を適当に選択された順序で用いることにより実施されることからなる前記特許請求の範囲第 1 項記載の方法。

- 5) 粗製された物質を樹脂から脱着することからなる前記特許請求の範囲第 1 項記載の方法。
- 6) 樹脂からの精製された物質の脱着が弱酸性の水、または水と極性溶媒との混合物を用いて溶離することにより実施されることからなる前記特許請求の範囲第 5 項記載の方法。
- 7) 樹脂上への選択的吸着による精製が発酵により得られたアントラサイクリノングリコシドおよび同様の合成化合物のいずれにも使用されうることからなる前記特許請求の範囲第 1 項記載の方法。

3. 発明の詳細な説明

本発明は樹脂上への選択的吸着によるアントラサイクリノングリコシドの精製法に関する。

前記グリコシドを実質上純粋な形態で取得するのに使用するための高度に特異的な方法を得る必要性は、発酵的製造法および合成的製造法のいずれにおいても粗生成物中における有機および無機不純物の量が特に高くそして平均12～25%まで達するという事実から主として生ずる。

しかしながら、塩素化された溶媒での粗生成物の抽出そして次に緩衝液での洗浄を行なう従来既知の精製操作による方法では、不純物%が相当低下しているにしてもなお4.5～5.0%の範囲にある最終生成物を生ずる。

一方では一般的に受容しうるものと考えられるが、前記の純度標準は配糖体分子の取扱および化学的試験に対する特別な感受性を考慮すると、実質上純粋な最終生成物の取得を可能にする改良された精製法の研究における興味を刺

激した。抗腫瘍剤としてのアントラサイクリノグリコシドの臨床的使用、そして薬用量および毒性という副次的問題を考慮しつつ、一般的に毒性の高い不純物の最適な除去を達成できることは本発明の明らかな有用性である。

不純物を最高2%の量で含有する最終生成物の取得を可能にする本発明の方法は粗生成物を酸性環境(pH 3～5)で種々のタイプの樹脂上に吸着させそして次に水または水と極性溶媒との混合物を用いて溶離する方法に実質的に基いている。より詳しくは、本発明方法は水溶性物質を溶解含有する弱酸性水性媒体を顆粒またはビードのような粒子中に分散された樹脂上に吸着させる段階および第1の段階において吸着された物質を脱着させる引続く段階を包含するものである。

吸着する樹脂は、実質上一般的に好都合には

樹脂粒子を充填した塔またはカラムの形状をした適当な容器中に含有されうる。粗生成物中に含有される不純物の種類の如何により、最初の樹脂からの物質の脱着により得られる溶出液は好都合には引続いて異なる型の樹脂上に吸着され、そこから次に既知方法で溶離されうる。

本発明のクロマトグラフィ精製法においては、重合体状且つイオン交換型またはカルボキシメチルセルロース型の吸着樹脂が使用された。精製すべき粗生成物に応じた種々の型の樹脂の使用における正しい選択および適当な順序そして吸着期間中の弱い酸性環境により、高純度の最終生成物の取得、塩素化有機溶媒使用の排除および優れた精製収率が得られる。

以下の非限定的例により本発明方法を説明する。

例 1

4-デメトキシダウノルビシンの精製

力価70.2%および不純物含量1.8%を有する精製状態の4-デメトキシ-ダウノルビン15.0gを0.5%酢酸ナトリウム溶液3.6ℓ中に溶解させる。酢酸の添加によりpH 4.7としたこの溶液を直径2.5cmのカラム中のアンバーライト(Amberlite®) XAD2型樹脂[ローム・アンド・ハース社製品]400ml上に吸着させる。生成物を水1000mlで洗いそして次に水/メタノール(5:1)(v/v)混合物を用いて溶離する。第1番目の溶出液として、アグリコンおよび種々の不純物を含有する溶液2000mlを集める。

水/メタノール(1:1)(v/v)混合物を用いて溶離を続けそして4500mlのフラクションを集める。溶液状態において溶出液は前記4-デメトキシ-ダウノルビシンを10%の不純物と共に含有する。

特開昭59-118797 (3)

この溶出液を塩酸の添加により pH 2.8 となし、そして次に真空下に濃縮して容積 1500 ml とする。濃縮された溶液に酢酸ナトリウムを添加することにより pH を 4.0 となし、そしてこの弱酸性溶液を直径 2.5 cm のカラム中に含有された CM セファロース (Sephacrose®) C1. 6B 型樹脂 (ファルマシア社製品) 150 ml 上に流量毎時 150 ml で吸着させる。吸着完了後、カラムを初め水 450 ml でそして次に 0.03 M 塩酸で溶離する。

不純物 1.8 % を含有する初めの溶出液 800 ml を酢酸ナトリウムの添加により pH 4.7 とし、そして第 1 番目の精製段階のアンバーライト XAD2 樹脂上に吸着させるべき粗製 4-デメトキシ-ダウノルビシンの溶液に加えて再循環させる。

純粋な 4-デメトキシ-ダウノルビシンを含有する続く溶出液 (3500 ml) を容積 50 ml とするまで真空濃縮する。アセトン 250 ml を加え、

得られた沈殿を濾過し、アセトンで洗いそして乾燥する。出発粗生成物に基いて計算して 52 % の収率で 4-デメトキシ-ダウノルビシンが力価 97 % および不純物含量 3 % 以下で得られる。

例 2

ダウノルビシンの精製

力価 74.2 % および不純物含量 8.5 % を有する塩素化ダウノルビシン 15.0 g を水 4500 ml 中に溶解させる。酢酸ナトリウムの添加によりこの溶液を pH 5.0 となし、そして直径 2.5 cm のカラム中の S112 カステル (Kastell®) 樹脂またはアンバーライト ER 180 型樹脂 (ローム・アンド・ハース社製品) 400 ml 上に流量毎時 600 ml (1.5 b.v.) で吸着させる。

この生成物を 1 % 塩化ナトリウム溶液 1000 ml で洗い、そして次に水/エタノール (1:1)

(v/v) 混合物で溶離する。

溶液中にアグリコンを含有する最初のフラクション (400 ml) を除去し、そして溶離を継続して純粋なダウノルビシンを含有する溶出液 260 ml を集める。希塩酸の添加により pH を 2.5 に調整し、アセトンを添加し、そして生成物を +5°C で 6 時間結晶化せしめる。生成物を濾過し、アセトンで洗い、そして 12 時間真空乾燥する。

出発粗生成物に基いて計算して収率 80 % でダウノルビシンが得られる。HPLC により測定して力価 97 %、不純物含量 2.6 % である。

例 3

4-デメトキシ-ドキシノルビシンの精製

不純物含量 1.4 % を有する 4-デメトキシ-ドキシノルビシン 10.4 g を含有する水溶液 2000 ml を直径 2.5 cm のカラム内に含有される ER 180 型樹脂 (ローム・アンド・ハース社製品) 50

ml 上に流量毎時 250 ml で吸着させる。

不純物の選択的吸着により部分的に精製された溶出液を次に CM セファロース C1. 6B 型樹脂 200 ml 上に吸着させる。生成物をメタノール/水/濃塩酸 (50:50:0.015) の混合物を用いて溶離し、アグリコンおよび他の不純物を含有する最初のフラクション (約 800 ml) を捨てる。次に純粋な物質を含有する溶出液 2000 ml を集め、そして 60 ml とするまで真空濃縮する。アセトン 300 ml を添加し、3 時間攪拌する。沈殿を濾過し、アセトンで洗い、そして乾燥する。不純物含量 3 % の純粋な 4-デメトキシ-ドキシノルビシン 6.5 g が理論上の 58.2 % の収率で得られる。

例 4

4'-デスオキシ-ドキシノルビシンの精製

力価 69.2 % として有機不純物含量 1.2 % ならびに鉍物塩不純物 1.2 % を有する 4'-デスオキ

特開昭59-118797 (4)

シードキソルビンシン15.0gを水2000ml中に溶解しそしてCMセフアデックス C25 型樹脂300ml上に流量毎時600mlで吸着させる。吸着が完了すると、溶液を0.03%塩酸で溶離しそして4'-デスオキシードキソルビンシンを含有するフラクション(6500ml)を得る。

前記溶出液を水酸化ナトリウム溶液の添加によりpH3.8となし、そしてこれを8112カステル樹脂200ml上に毎時400mlの流量で吸着させる。生成物を水600mlで洗いそして次に塩酸の添加によりpH2.0に酸性化したメタノールで溶離する。

コア溶出液600mlを得、これを真空濃縮して60mlとなす。攪拌しながら、この濃縮した溶液をアセトン600ml中に徐々に加える。形成された沈殿を濾過し、アセトンで洗いそして乾燥する。

mlを集める。

コア溶出液を1500mlまで濃縮し、炭酸ナトリウムの添加によりpH4.8となしそして直径25cmのカラム内に含有されるカルボキシメチルセルロース「ワスマン(Watman®)」樹脂250ml上に毎時500ml(2b.v.)の流量で吸着させる。

吸着が完了すると、生成物をエタノール/水/濃塩酸(99.3:0.7:0.015)混合物で洗いそして次にエタノール/水/濃塩酸(90:10:0.05)の混合物で溶離してコア溶出液3200mlを集める。

溶出液を60mlとなるまで真空濃縮しそしてアセトン300mlの添加により生成物を沈殿させる。

力価9.12%および不純物含量3%を有する4'-エビードキソルビンシン6.9gが得られる。収率55.3%。

力価9.58%および不純物含量4.2%を有する4'-デスオキシードキソルビンシンが理論上の61%の収率で得られる。

例 5

4'-エビードキソルビンシンの精製

力価7.59%および不純物含量15%を有する粗製4'-エビードキソルビンシン15.0gを水4000ml中に溶解させる。

炭酸ナトリウムの添加によりこの溶液をpH4.8となしそして直径2.5cmのカラム内に含有されるアンバーライト IRC 724 型樹脂400ml上に毎時1600ml(4b.v.)の流量で吸着させる。

カラムを水800mlで洗いそして次にメタノール/水/濃塩酸(95:5:0.015)の混合物を用いて溶離する。まだ10%の不純物を含有する4'-エビードキソルビンシンを含有するコア溶出液4000mlおよび不純物含量の多い後部溶出液1500

例 6

ドキソルビンシンの精製

(a) ドキソルビンシン70gを水2.8ℓ中に溶解させる。緩衝液の添加によりpH3.7~4.5となしそしてこの溶液を直径6cmを有するカラム内に含有される8112カステル樹脂2ℓ上に吸着させる。生成物を水35ℓおよびメタノール15ℓの混合物で溶離する。

溶出液(40ℓ)を0.5ℓとなるまで真空濃縮しそして5℃で3時間攪拌しながらエタノール1ℓおよびアセトン4.5ℓの混合物を添加することにより生成物を結晶化させる。

この生成物を濾過し、0.8ℓのアセトンで洗いそして40℃で5時間真空乾燥する。1回精製されたドキソルビンシン(I)56.0gが得られる。

(b) 前記方法(a)で得られた1回精製ドキソルビンシン(I)80.0gを水2.4ℓ中に溶解させそして緩

衡液の添加により pH 4.0 となす。

この溶液を直径 1.2 cm を有しそしてカルボキシメチルセルロースワスマン樹脂 1.6 g を含有するカラムに吸着させる。

カラム流出液を除去する。水 3.2 ml で洗ったのち、生成物を塩酸の添加により pH 2.5 とした水 5.5 ml を用いて溶離する。

溶出液 4.6 ml を集めそして真空下に 0.6 ml となるまで濃縮しそしてイソプロパノール/アセトン (1:3) 混合物の注意深い添加により生成物を結晶化せしめる。

生成物を尹過し、アセトン 1 ml で洗いそして +40℃ で 4 時間乾燥する。力価 98.5% および不純物含量 1.5% を有するドヤソルビシン 6.5 g が得られる。